The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic …
K Takkavatakarn, T Thammathiwat… - Clinical Kidney …, 2023 - academic.oup.com
Renal anemia in chronic kidney disease (CKD) is associated with poor outcomes. Hypoxia-
inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and …
inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and …
Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta …
L Zheng, J Tian, D Liu, Y Zhao, X Fang… - British journal of …, 2022 - Wiley Online Library
Aims Renal anaemia is a common complication of chronic kidney disease (CKD).
Roxadustat is the first‐in‐class oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for …
Roxadustat is the first‐in‐class oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for …
Safety and efficacy of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis and trial sequential analysis
C Liu, Z Fu, J Jiang, K Chi, X Geng, Z Mao… - Frontiers in …, 2021 - frontiersin.org
Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI),
has been used to treat anemia in patients with chronic kidney disease (CKD). However, its …
has been used to treat anemia in patients with chronic kidney disease (CKD). However, its …
[HTML][HTML] The efficacy and safety of roxadustat for the treatment of posttransplantation anemia: a randomized study
W Kong, X Wu, Z Shen, M Wang, X Liu, X Lin… - Kidney International …, 2024 - Elsevier
Introduction Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH)
inhibitor, can stimulate erythropoiesis. Our objective was to evaluate the efficacy and safety …
inhibitor, can stimulate erythropoiesis. Our objective was to evaluate the efficacy and safety …
罗沙司他治疗肾性贫血的快速卫生技术评估.
陈静， 成华， 李亚利， 刘洋， 孙文芳… - … & Analysis of Drug …, 2022 - search.ebscohost.com
摘要目的: 通过对罗沙司他治疗肾性贫血有效性, 安全性和经济性的快速卫生技术评估,
为临床合理用药提供循证证据. 方法: 检索the Cochrane Library, PubMed …
为临床合理用药提供循证证据. 方法: 检索the Cochrane Library, PubMed …
Comparative pharmacoeconomic analysis of the use of epoetin alfa and roxadustat in combination with iron supplements in adult patients with anemia against the …
IS Krysanov, EV Makarova, VY Ermakova… - Clinical …, 2024 - journals.eco-vector.com
Objective. Evaluation of the clinical and economic effectiveness of the use of epoetin alfa or
roxadustat in combination with iron supplements in adult patients with anemia due to chronic …
roxadustat in combination with iron supplements in adult patients with anemia due to chronic …
Perbandingan efektivitas dan keamanan antara roxadustat dan epoetin alfa sebagai terapi anemia pada pasien yang menjalani hemodialisis reguler: meta analisis
KWS Karya, NLP Praptika, NYT Nurbudhi… - Intisari Sains …, 2021 - pop3.isainsmedis.id
Introduction: Chronic kidney disease (CKD) is a global health problem. Hemodialysis (HD) is
one of the treatment modalities for end-stage renal disease which is commonly used. A …
one of the treatment modalities for end-stage renal disease which is commonly used. A …
[PDF][PDF] The efficacy and safety of roxadustat in anemia treatment in hemodialysis patients with erythropoietin-hyporesponsiveness
Y Zou, D Chang, AY Wang, J He, M Li, Y Cai, J Wei… - 2022 - scholar.archive.org
Background Erythropoietin is an important drug for the treatment of anemia in hemodialysis
patients. However, many patients show erythropoietin-hyporesponsiveness. Roxadustat has …
patients. However, many patients show erythropoietin-hyporesponsiveness. Roxadustat has …